Tumor markers: An important adjunct to clinical practice

Southern Medical Journal

Volumn 99, Issue 2, 2006, Pages 107-

  Sachdev, Mankanwal S ^a   Tombazzi, Claudio R ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

CLINICAL FEATURE; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EDITORIAL; HEPATOBILIARY SYSTEM CANCER; HUMAN; MEDICAL PRACTICE; MIRIZZI SYNDROME; PANCREAS CANCER; BILE DUCT TUMOR; BLOOD; CARCINOMA; COMPARATIVE STUDY; NOTE;

CA-19-9 ANTIGEN; CARCINOMA; COMMON BILE DUCT NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 33644983452     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000198307.88105.c4     Document Type: Editorial

References (7)

1. Sanchez M, Gomes H, Marcus EN. Elevated CA 19-9 Levels in a Patient with Mirizzi's Syndrome: Case Report. South Med J 2006;99:160-163.
2. Lee KC, Yamazaki O, Horii K, et al. Mirizzi syndrome caused by xanthogranulomatous cholecystitis: report of a case. Surg Today 1997;27:757-761.
3. Principe A, Del Gaudio M, Grazi GL, et al. Mirizzi syndrome with cholecysto-choledocal fistula with a high CA19-9 level mimicking biliary malignancies: a case report. Hepatogastroenterology 2003;50:1259-1262.
4. Duffy MJ. Evidence for the clinical use of tumour markers. Ann Clin Biochem 2004;41(Pt 5):370-377.
5. Pleskow DK, Berger HJ, Gyves J, et al. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer [see comment]. Ann Intern Med 1989;110:704-709.
6. Pavai S, Yap SF. The clinical significance of elevated levels of serum CA 19-9. Med J Malaysia 2003;58:667-672.
7. Moon JH, Cho YD, Cheon YK, et al. Wire-guided intraductal US in the assessment of bile duct strictures with Mirizzi syndrome-like features at ERCP. Gastrointest Endosc 2002;56:873-879.